Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04323748
PHASE1

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Sponsor: New York Medical College

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.

Official title: The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Key Details

Gender

All

Age Range

1 Year - 21 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2021-02-24

Completion Date

2027-07-31

Last Updated

2026-04-15

Healthy Volunteers

No

Interventions

DRUG

rituxan

The dose dense administration of rituximab will consist of 5 doses total Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2

Locations (1)

New York Medical College

Vahalla, New York, United States